Regular users of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) are at reduced risk of colon cancer, but the evidence for protective effects of NSAIDs elsewhere in the digestive tract is scant. We investigated the association between the use of NSAIDs and risk of esophageal and gastric cancer, using data from a large population-based, case-control study. Cases were individuals,...

The Fifth edition of the World Health Organization classification digestive system and American Joint Committee on Cancer staging manual contain substantial refinements information for esophageal tumors. epithelial tumors esophagus are classified as benign, dysplasia, malignant groups. Dysplasia is divided into Barrett dysplasia squamous graded either low-grade or high-grade. Malignant often ad...

PURPOSE Adenocarcinomas of the distal esophagus and gastric cardia are two tumors that have many features in common. They have similar prognoses, treatment modalities, and patterns of dissemination. The etiology is different, with gastroesophageal reflux disease playing a major role for esophageal adenocarcinoma, in contrast to adenocarcinoma of the gastric cardia. In the present study, we inve...

The origin of the progenitor cell for Barrett's esophagus remains a major unsolved mystery. Understanding the source of this progenitor may improve strategies to prevent the development of esophageal adenocarcinoma. Esophageal submucosal glands (ESMGs) and ducts may serve as a potential source of progenitor cells that respond to esophageal injury. Through the use of human histologic and molecul...

Barrett esophagus was found in seven members of a single family. Two of these patients also had adenocarcinoma of the gastroesophageal junction. Among family members who did not have Barrett epithelium, one had esophageal ulcerations with dysplasia in squamous epithelium and another had an esophageal stricture. The pattern of involvement suggests autosomal dominant inheritance of Barrett esopha...

Although T2,N0,M0 esophageal adenocarcinoma is grouped with other locoregional disease by NCCN, no consensus exists about how it should be treated. One of the inherent complexities of treating T2,N0,M0 esophageal adenocarcinoma is the inaccuracy of the clinical staging. In addition, conflicting evidence exists about whether neoadjuvant therapy adds any benefit to esophagectomy. A 52-year-old pa...

Esophageal adenocarcinoma is an aggressive malignancy with a poor prognosis. In Western countries, the incidence of esophageal adenocarcinoma has increased dramatically in the last three decades. To improve patient survival and reduce disease burden, early-stage detection, or better yet, preventing the progression of esophageal adenocarcinoma from its premalignant lesions, constitute the best s...

Esophageal cancer has a poor overall prognosis and is frequently diagnosed at a late stage. Conventional treatment for metastatic esophageal cancer involves chemotherapy and radiation. Local disease control plays a significant role in improving survival. Endoscopic spray cryotherapy is a novel modality that involves freezing and thawing to produce local ablation of malignant tissue via ischemic...

The outcome for patients diagnosed with esophageal adenocarcinoma remains abysmal despite a better understanding of the molecular events that underlie development of the disease. Additionally, the incidence for this type of esophageal carcinoma has been rapidly increasing in the United States over the last three decades (1). Esophageal adenocarcinoma often occurs in the setting of Barrett’s eso...

Metastatic esophageal adenocarcinoma to the urinary bladder is extremely rare. We describe a previously healthy 49-year-old female with recent diagnosis of adenocarcinoma of the gastroesophageal junction with metastatic disease to the liver. Biopsy was positive for human epidermal growth factor receptor 2 (HER2) by Fluorescence In Situ Hybridization (FISH). She received six cycles of Cisplatin,...